Form 8-K - Current report:
SEC Accession No. 0000950170-25-004587
Filing Date
2025-01-13
Accepted
2025-01-13 08:30:33
Documents
13
Period of Report
2025-01-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20250112.htm   iXBRL 8-K 45480
2 EX-99.1 rare-ex99_1.htm EX-99.1 42051
3 GRAPHIC img45776771_0.jpg GRAPHIC 19924
  Complete submission text file 0000950170-25-004587.txt   234203

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20250112.xsd EX-101.SCH 23898
15 EXTRACTED XBRL INSTANCE DOCUMENT rare-20250112_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 25524970
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)